Cognision

Cognision operates at the intersection of neuroscience and digital health, providing a unified platform called Cognision360™ for electronic-sourced digital biomarkers in central nervous system (CNS) clinical trials and research. The company leverages quantitative EEG (qEEG), Event-Related Potentials (ERP), polysomnography, eye-tracking, and wearable sensor data to deliver objective measures of cognitive and cortical function. Its technology is positioned to address the need for sensitive, reliable, and scalable tools in drug development for neurological disorders and cognitive research. As a private company, it appears to be in an early-revenue or pre-revenue stage, serving biopharma clients and research institutions.

Cognision360™: A unified platform for electronic-sourced digital biomarkers integrating qEEG, ERP, polysomnography, eye-tracking, wearable sensor data, and cognitive test administration for CNS clinical trials and research.

Cognision competes in the digital biomarker and clinical trial technology space against companies offering EEG/ERP solutions (e.g., Compumedics, Natus), wearable sensor platforms, and digital cognitive assessment tools. Its key differentiator is the integrated Cognision360™ platform that unifies multiple data sources into a single analysis pipeline for CNS trials.